



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow -226021

CIN: L85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Date: 22.06.2026

To,

**National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor,
Plot No. C /1, G Block, Bandra - Kurla Complex,
Bandra (E), Mumbai – 400051, Maharashtra, India.**

Trading Symbol: CHANDAN

ISIN: INE0B2N01016

Subject: Submission of Investor Presentation for Q4 and FY26

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit herewith the Investor Presentation of Chandan Healthcare Limited highlighting the operational and financial performance of the Company for the quarter and financial year ended March 31, 2026.

The presentation, inter alia, contains key financial and operational highlights, business updates, expansion initiatives, strategic developments and future growth outlook of the Company for the information of investors and stakeholders.

The aforesaid Investor Presentation is also being made available on the website of the Company.

You are requested to take the above information on record.

For Chandan Healthcare limited

**Rajeev Kumar Nain
Company Secretary and Compliance Officer**

Enclosed: As above



Chandan Healthcare Limited

Investor Presentation Q4 & FY26



This presentation and the accompanying slides (the Presentation), which have been prepared by **Chandan Healthcare (Chandan, The Company)** solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks.

The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Amar Singh

Promoter, Chairman and Managing Director

We are pleased to conclude FY26 on a strong note with Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and PAT of ₹27.06 Cr. FY26 has been a year of expansion, strategic investments and network growth for Chandan Healthcare as we continued to strengthen our operational presence across multiple regions while building long-term growth capabilities for the business.

During the quarter, we expanded our network presence through new diagnostic centre launches in Mumbai, Kolkata and Raipur while also accelerating the rollout of our exclusive Jeena Sikho partnership across Punjab, Haryana, Meerut, Lucknow and Kota. We also strengthened our institutional healthcare presence through multiple long-term government healthcare projects across Punjab, Rohtak and Assam, supporting long-term revenue visibility and expanding our advanced radiology capabilities across key healthcare markets.


Looking ahead, we remain optimistic about the opportunities in the Indian diagnostics industry and continue to focus on expanding our pan-India centre network, improving utilisation across newly launched centres and strengthening network coverage through our partnership-led growth strategy with Jeena Sikho. We remain committed towards building a scalable, integrated and high-quality diagnostics platform with sustainable long-term growth visibility




Q4 FY26 Consolidated Key Financials Highlights




Total Income



EBITDA PAT



EBITDA % PAT %




All Amount In ₹ Cr & Margins In %


FY26 Consolidated Key Financials Highlights




Total Income



EBITDA PAT



EBITDA % PAT %



All Amount In ₹ Cr & Margins In %

Q4 & FY26 Consolidated Profit & Loss Statement



In ₹ Cr

Particulars	Q4 FY26	Q4 FY25	Y-O-Y	FY26	FY25	Y-O-Y
Operating Income	75.58	62.65		276.39	230.12	
Other Income	1.82	2.42		4.28	2.94	
Total Income	77.41	65.07	18.96%	280.67	233.06	20.43%
Raw Material Expenses	34.75	30.41		133.68	107.62	
Employee Benefit Expenses	12.90	9.72		44.20	38.86	
Other expenses	15.51	12.28		45.95	43.19	
Total Expenditure	63.15	52.42		223.83	189.67	
EBITDA	14.25	12.65	12.65%	56.84	43.39	31.02%
EBITDA (%)	18.41%	19.44%		20.25%	18.62%	
Finance Costs	1.80	1.30		5.88	4.58	
Depreciation	2.45	2.70		9.78	6.74	
PBT	10.00	8.66	15.50%	41.18	32.07	28.43%
Exceptional Items	0.69	0.00		2.92	0.00	
Tax	2.30	2.56		9.71	8.55	
PAT	7.01	6.10	15.05%	28.55	23.52	21.42%
Minority Interest	0.10	0.07		1.50	1.35	
Reported Net Profit	6.92	6.02	14.88%	27.06	22.17	22.04%
PAT (%)	8.94%	9.25%		9.64%	9.51%	
EPS (Diluted)	2.53	2.64		10.76	10.78	

Aggressive Multi-City Rollout of Exclusive Jeena Sikho Partnership Across India

Punjab Entry – Dera Bassi (HiiMS Panchkula)

- Commenced diagnostic operations at a 100+ bed partner hospital facility
- Marked entry into Punjab through institutional hospital model
- Operations initiated post successful trial runs
- Expected to generate steady captive volumes from IPD and OPD



Meerut Expansion – Muradnagar Facility

- Commenced diagnostic operations at a 600+ bed partner hospital
- High patient volumes supporting strong diagnostic demand
- Strengthens presence in a key North India market
- Scales up operations within the existing network



Haryana Entry – Kurukshetra Facility

- Commenced diagnostic operations in Haryana, expanding geographic reach
- Located within an integrated partner hospital facility
- Captive demand model driving consistent utilisation
- Strengthens presence across high-demand regions



Lucknow & Kota Rollout

- Expanded operations within Lucknow, strengthening core market presence
- Commenced diagnostic operations in Kota, Rajasthan
- Multi-city rollout across partner hospital network
- Supports scalable expansion through institutional partnerships



Exclusive Diagnostic Partner
For Jeena Sikho's Pan-India Network

50%+ Facilities Operationalized
Across 13 States; 100% Targeted In FY27

Building Long-Term Revenue Visibility Through Government PPP Projects



Punjab PPP Projects – District Hospitals

- PPP projects across district hospitals in Punjab
- Installation of 1.5 Tesla MRI scanners and 32-slice CT scan
- Locations include Hoshiarpur, SBS Nagar, Kapurthala and Dasuya
- Additional projects at Fazilka, Sri Mukatsar Sahib, Firozpur and Abohar
- Estimated project value of ₹25–26 Cr



Rohtak MRI Project – Government Hospital

- 10-year project at Civil Hospital, Rohtak
- Installation of 1.5 Tesla MRI system
- 200-bedded hospital with 40,000+ monthly OPD footfall
- Provides sustained revenue visibility and operational stability
- Expands presence in government healthcare segment



Assam PPP Project – Railway Hospital

- 10-year PPP at Northeast Frontier Railway Central Hospital
- Development and operation of advanced radiology diagnostic centre
- Equipped with 3 Tesla MRI and 128-slice CT scan
- Includes X-ray, USG and Colour Doppler
- Covers both inpatient and outpatient diagnostic services

Enhancing Network Reach Across Metro and Emerging Cities




Mumbai – Access to a Large, High-Density Patient Market

- Entry into Maharashtra with launch of diagnostic centre in Mumbai
- Offers comprehensive diagnostic services including pathology and advanced tests
- Equipped with TMT, ECG, EEG and PFT capabilities
- Planned addition of X-Ray and BMD services



Kolkata – Building Presence in Eastern India

- Entry into West Bengal with launch of diagnostic centre in Kolkata
- Focus on comprehensive blood investigation services
- Planned upgrade with X-Ray and BMD capabilities
- Supports patients from associated partner centres
- Enables seamless network integration



Raipur – Expanding into Emerging Urban Markets

- Entry into Chhattisgarh with launch of diagnostic centre in Raipur
- Offers pathology, blood investigations and advanced diagnostic tests
- Equipped with TMT, ECG, EEG and PFT with provision for CT and MRI
- Designed to cater to wide patient base and network demand
- Strengthens presence in emerging urban market



Company Overview

Redefining Diagnostics & Pharmacy in North India

Chandan Healthcare Limited is one of the leading provider of diagnostic and pharmacy services, and a key entity within the Chandan Group. The Company offers a comprehensive suite of NABL/NABH-accredited pathology and radiology solutions across India.

Its service portfolio includes a wide range of diagnostic tests such as blood tests, X-ray, ECG, ultrasound, CT scan, MRI, and other specialized investigations, ensuring reliable and high-quality care.

Chandan operates through a diverse business model spanning B2C (retail customers), B2B (institutional partnerships), and B2G (government PPP contracts) all under a company-owned model that guarantees consistent standards and operational control.

To capture rising demand across urban and semi-urban markets, Chandan is actively expanding into neighboring states including Delhi, Rajasthan, Bihar, Chhattisgarh, and Madhya Pradesh, Punjab, Maharashtra, West Bengal, Gujarat, Assam & Haryana with a strategic focus on metro hubs and Tier 2/3 cities.

The company got listed on NSE Emerge on 17th February 2025



Key Facts & Figures



20+
Years Of Industry Experience



20 Lakh
Total Patient Count (FY26)



1900+
Team Size



88 Lakh +
Total Test Conducted (FY26)



360
Collection Centres



**NABH MIS
Accreditation**
For 6 centres



78+
Diagnostic
Centres & Labs



NABL Accreditation
For 16 Labs



Presence **62 Cities**
Across **16 States**



500 +
Radiology Tests Offered




3,000 +
Pathology Tests Offered




FY26
Revenue: ₹ 276.39 Cr
EBITDA: ₹ 56.84 Cr
PAT: ₹ 27.06 Cr



Key Events & Achievements







Amar Singh

Promoter, Chairman and Managing Director

MBBS with 20+ years of experience in the healthcare industry



Asmita Singh

Promoter and Managing Director

BBA and MBA with 20+ years of marketing experience



Vinay Lamba

Non-Executive Director

Marine Engineer with 10+ years of experience in technical operations & equipment strategy



Amit Gupta

Non Executive Independent Director

B.Sc. and FCS with 20+ years of experience in corporate compliance and secretarial practice.



Brahma Nand Bhartiya

Non Executive Independent Director

B.A., M.A. with experience in labour administration; retired Assistant Labour Commissioner, UP.



Vinod Jain

Independent Director

MS (General Surgery) with fellowships from ACS and ICS.




Business Overview

Multi-Segment Model Driving Growth Across B2C, B2B & B2G



Pathology

FY26 Revenue
₹119.48 Cr
(43.23%)



Radiology

FY26 Revenue
₹36.70 Cr
(13.28%)



Pharmacy

FY26 Revenue
₹120.22 Cr
(43.50%)

Diversified Revenue Streams Ensure Stability, Scalability, & Reduced Risk.



B2C (Retail Diagnostics)

- Walk-in services across **62+ cities & 16 states**
- **20L+ patients served** in FY26
- Strong brand recall, reliable service, affordable care

FY26 Revenue
₹111 Cr
(40%)



B2B (Institutional Clients)

- **230+ private hospitals & clinics** as partners
- Recurring, long-term relationships
- Steady revenue from integrated tie-ups

FY26 Revenue
₹83 Cr
(30%)



B2G (Government PPPs)

- Public-Private Partnerships with **state governments**
- Diagnostic services in government hospitals
- Long-term contracts ensure stable cash flow & credibility

FY26 Revenue
₹83 Cr
(30%)




Comprehensive Diagnostic Centre (Total 23)

Pathology + Advanced Radiology

- Complete diagnostic solution under one roof
- Offers pathology, MRI, CT, Ultrasound, X-ray and other imaging services
- One-stop diagnostic destination
- Regional diagnostic hub

Top Performing Centre

- Name – Lucknow, Indira Nagar
- Revenue – ₹ 9.98 Cr



Diagnostic Centre (Total 16)

Pathology + X-Ray

- Full range of pathology testing services
- Equipped with conventional X-ray facilities
- Addresses routine diagnostic requirements

Top Performing Centre

- Name – Lucknow, Vijay Khand, Gomti Nagar
- Revenue – ₹ 1.04 Cr



Radiology Centre (Total 14)

Dedicated Imaging Facility

- Focused exclusively on radiology and imaging
- MRI, CT Scan, Ultrasound, Mammography & X-ray
- Supports advanced disease diagnosis and treatment planning

Top Performing Centre

- Name – Lucknow, Vijay Khand, Gomti Nagar
- Revenue – ₹ 1.05 Cr



Standalone Lab (Total 25)

Dedicated Pathology Laboratory

- Performs wide range of tests across multiple disciplines
- Delivers accurate and timely reporting
- Supports preventive and clinical healthcare needs



Franchise Centre (FOFO Model) (235)


Sample Collection & Patient Service Centre

- Patient registration and sample collection
- Testing conducted through designated central laboratories
- Asset-light model enabling wider geographic reach

Top Performing Centre

- Name – Shahjahanpur
- Revenue – ₹ 18 Lakhs

Expansive Regional Footprint Across North & Central India



Glimpse Of Chandan's Diagnostic Centres




Certified By India's Top Accrediting Bodies




Recognized For Quality Care With 6 NABH-Accredited Centres And 16 NABL- Certified Labs.

NABH Indira Nagar



NABH MKP Chowk



NABH Prayagraj



NABL Indira Nagar



NABL MKP Chowk UK



NABL Karachi Khana






Chandan 24x7

100K+ Downloads
On Play store

- 90+ Specialties
- 24x7 Access
- One App for All Healthcare Needs
- Online Consultations & Home Sample

Available On
IOS



Digital-first platform strengthening customer loyalty & operational efficiency

Unified Platform

Diagnostics, Pharmacy & Doctor Consultations

Seamless Integration

Offline + Online network, centralized medical records

Patient-Centric Features

- Lab test bookings, full-body health check-ups, home sample collection
- Appointments across **90+ medical specialties**
- Digital reports, prescriptions, purchase history
- Instant support via call centre

Chandan Family Loyalty Card

An integrated healthcare membership programme offering patients savings, convenience & holistic family coverage.



DISCOUNT COUPON

Full Body Checkup HIM-1 (51 Tests) MRP- ₹ 3550/- ₹ 999/- Avail 70% Discount	Advance Full Body Checkup HIM-2 (79 Tests) MRP- ₹ 5550/- ₹ 1499/- Avail 70% Discount
--------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------

+ Additional Discount upto 50%

Extra 25% Discount on above Checkups
 Extra 50% Discount for family members on the same day on same registered mobile number.

Free Home Sample Collection
Book Now
 0 80693 66666

www.chandanmedicalcentre.com

Scan the QR code to download Chandan24x7 app

<p>Cardholders Till Date: 40 Lakhs+</p>	<p>Adding Cardholders Every Month: 2 Lakhs+</p>
----------------------------------------------------	------------------------------------------------------------



Key Privileges

- Up to 70% savings on Preventive Health check ups & 10% cash back in all services
- Discounts on medicines via app & stores
- Free home sample pick-up & 2-hr delivery
- Instant reports & 24x7 support



Strategic Impact for Chandan

- Boosts customer loyalty & repeat use
- Enables cross-selling across services
- Creates recurring revenue stream
- Strengthens North India market position

Pharmacy Segment – Strong Complement To Diagnostics



Widespread Retail Network:

45 company-owned outlets across Uttar Pradesh, Uttarakhand, Madhya Pradesh, Chhattisgarh & Delhi



Wholesale Distribution Strength:

Centralised supply chain with cold-chain compliance ensures uninterrupted medicine availability



Integrated Healthcare Advantage:

Pharmacy complements diagnostics – boosting customer stickiness, cross-selling & loyalty



Pharmacy
Contribution



₹119.75 Cr




82.72% of
revenue

Pharmacy Remains A Supportive And Complementary Vertical, While The Company's Strategic Focus Will Continue To Be On Scaling Its Core Diagnostics Business



Key Strengths Driving Sustainable Growth





Network Expansion Plan

- Targeting a network of **100 labs across 17 states** over the next 3 years
- Built 235+ franchises this year; targeting 1,000 operational franchises in 24 months
- Enhancing accessibility and strengthening nationwide reach



Strategic Partnership with Jeena Sikho Lifecare Limited

- Chandan Healthcare to act as the **exclusive diagnostics partner** across 23 states and 100+ cities
- Extends to upcoming Jeena Sikho facilities as their network expands
- Providing end-to-end pathology and radiology services for IPD and OPD patients



Expansion Highlights


- **One District, One Lab:** Phased rollout across UP & Uttarakhand in 2 years
- **High-End Diagnostics:** PET-CT in Gorakhpur & Kanpur; Genome Lab in Lucknow
- **Preventive Health:** Expanding health check-ups in Tier 2 & Tier 3 markets



Growth via Chandan Medical Centres (CMC)

- Plan to open **20+ new CMCs annually** under structured, long-term strategy
- Expanding **affordable, quality diagnostics** across underserved regions
- Delivering **integrated healthcare services closer to communities**

Future Roadmap: Chandan Healthcare





Industry Overview

Healthcare Demand Rising Across India's Metro & Tier-2/3 Cities



The Indian healthcare market is projected to grow from approximately US\$ 367 billion by 2023 to US\$ 638 billion by 2025, representing a robust CAGR of ~22%



Public health expenditure has steadily increased, reaching around 2.1% of GDP in FY23, up from 1.6% in FY21, with a target of increasing further toward 2.5% in coming years



India is now the 4th largest medical device market globally, expected to grow rapidly



India's retail pharmacy and wellness sector will grow from US\$ 2.6 billion in 2023 to US\$ 4.1 billion by 2027 at 12% CAGR.




medical tourism sector was estimated at US\$ 7.4 billion in 2022 and is projected to cross US\$ 42 billion by 2032, making India a key destination for international patients

Source: IBEF Healthcare Feb 2025, Business Today

The Indian Healthcare Sector Is Entering Its Golden Decade.


Indian Healthcare Industry Size in (US\$ Billion)





Market Size & Growth

- Diagnostics industry expected to grow from US\$13 Billion (FY23) to US\$25 Billion (FY28) at a 14% CAGR.
- Growth driven by rising chronic diseases, ageing population, demand for preventive tests, and wider insurance coverage



Pathology Segment

- Accounts for 58% of the diagnostics market, currently valued at US\$7.5 Billion, projected to reach US\$14.4 Billion by FY28.
- India has ~1.32 lakh pathology labs, with 60%+ operating as standalone centres



Radiology Segment

- Comprises soft (X-ray, ultrasound) and advanced (CT, MRI, nuclear imaging).
- Market projected to reach US\$11 Billion by FY28, with growth led by demand in Tier 2/3 cities and advanced diagnostics.
- India has 55,000+ radiology labs, over 80% of which are standalone.




Market Structure & Opportunities

- Highly fragmented: 46% standalone, 28% private hospital labs, and 6% national chains.
- Low test prices vs developed countries indicate room for price realization and margin expansion.
- Fragmentation opens scope for consolidation and scalable models.



Healthcare Infrastructure Gap

India faces a shortfall of 3 million hospital beds, underscoring the urgent need for capacity expansion across healthcare and diagnostics.



**From Illness Detection To Preventive Care Diagnostics
Is Entering A New Era.**



Financial Overview

Consistent Growth Backed by Scale, Efficiency & Expansion

Year On Year Revenue
Growth

20.43%

Fixed Asset Turnover

2.44 Times

Interest Coverage

8.00 Times

Return on Equity

16.70%

Year on Year Profit
Growth

22.04%

Return on capital
Employed

20.94%

Debt to Equity

0.31 Times

Book Value


₹ 69.93

Key Financial Highlights




(All Amount In ₹ Cr & Margins In %)


Total Income



EBITDA



PAT



The Company demonstrated exceptional financial growth over FY24 to FY26. Total Income increased by 57.85%, rising from ₹176.59 Cr to ₹280.67 Cr, reflecting strong business expansion. EBITDA surged by 105.83%, from ₹27.72 Cr to ₹56.84 Cr, driven by improved operating leverage and cost efficiencies. PAT rose by 55.23%, from ₹16.27 Cr to ₹27.06 Cr, indicating sharp gains in profitability and bottom-line strength.

Consolidated Profit & Loss Statement



(In ₹ Cr)

Particulars	FY24	FY25	FY26
Revenues	176.59	230.12	276.39
Other Income	1.22	2.94	4.28
Total Income	177.81	233.06	280.67
Raw Material Expenses	80.85	107.62	133.68
Employee Costs	35.42	38.86	44.20
Other Expenses	33.92	43.19	45.95
Total Expenditure	150.19	189.67	223.83
EBITDA	27.62	43.39	56.84
Finance Costs	2.75	4.58	5.88
Depreciation	3.40	6.74	9.78
PBT	21.46	32.07	41.18
	0.00	0.00	2.92
Tax	5.11	8.55	9.71
Minority Interest	0.08	1.35	1.50
PAT	16.27	22.17	27.06

Consolidated Balance Sheet



(In ₹ Cr)





Equities & Liabilities	FY24	FY25	FY26	Assets	FY24	FY25	FY26
Equity	20.00	24.45	24.45	Non-Current Assets			
Reserves And Surplus	21.16	98.15	146.54	Fixed assets	48.49	80.45	113.23
Total Equity	41.16	122.60	171.00	Non-Current Investments	3.38	17.32	7.85
Non-Current Liabilities				Deferred Tax Assets (Net)	-	0.18	0.26
Long Term Borrowings	12.18	22.14	28.97	Other Non Current Assets	3.67	2.54	3.47
Other Long-Term Liabilities	-	-		Total Non-Current Assets	56.74	100.49	124.81
Long Term Provision	1.39	3.46	4.63	Current Assets			
Deferred Tax Liabilities	3.06	1.90	2.36	Inventories	18.24	31.37	33.74
Total Non-Current Liabilities	16.63	27.51	35.96	Trade Receivables	28.61	47.26	86.40
Current Liabilities				Cash & Bank Balance	3.90	6.21	3.58
Short Term Borrowings	23.74	26.02	24.77	Other Current Assets	2.36	5.69	11.24
Trade Payables	19.51	25.94	40.90	Other Current Financial Assets	8.22	19.94	29.74
Short Term Provisions	0.35	0.69	1.07	Total Current Assets	61.33	110.47	164.71
Other Current Liabilities	14.23	4.39	10.52	Total Assets	118.07	210.96	289.52
Total Current Liabilities	57.82	57.04	77.27				
Total Equity & Liabilities	118.07	210.96	289.52				

Consolidated Cash Flow Statement



(In ₹ Cr)

Particulars	FY24	FY25	FY26
Cash Flow from Operating Activities	1.12	-2.75	16.17
Cash Flow from Investing Activities	-14.83	-62.04	-39.90
Cash Flow from Financing Activities	15.57	67.11	21.10
Net Increase in Cash & Cash Equivalents	1.86	2.31	-2.63




As On 22-06-2026

As On 31-03-2026


NSE (CHANDAN | INEOB2N01016)

Share Price (₹)	212.75
Market Capitalization (₹ Cr)	520.22
No. of Shares Outstanding	2,44,52,064
Face Value (₹)	10.00
52-week High-Low (₹)	358.00 - 184.50

Share Holding Pattern



Share Performance From 17th February 2025 Till Date



Widespread Presence with operations across 62+ cities in 16 states, enabling deep regional penetration and first-mover advantage in underserved areas.



Integrated Diagnostics Chain offering both pathology and radiology services under one roof, driving patient stickiness and cross-selling opportunities.



Volume-Led Growth Strategy with a scalable model anchored in in-house labs, B2B referral partnerships, and low-cost collections infrastructure.



Focused Expansion in Tier 2/3 Markets, including recent entry into Delhi, Madhya Pradesh and Chhattisgarh, targeting high-growth diagnostics demand.



Experienced Promoter-Led Team with 20+ years in healthcare operations, marketing, and diagnostics strategy.



Core Diagnostics Business Drives Revenue, supported by strong unit economics, high margin radiology services, and rising test volumes.



Accredited Infrastructure including NABL-certified central labs, ensuring quality, compliance, and eligibility for government and insurance linked programmes.

Thank You



Chandan Healthcare Limited

Biotech Park, Kursi Road, Lucknow 226021 U.P.

Email: care@chandan.co.in

Phone: 08069366666

Website: www.chandandiagnostic.com



Kirin Advisors Private Limited

713-B, Lodha Supremus II, Wagle Estate,

Thane West - 400 604

E-mail: info@kirinadvisors.com

Phone: 022 4100 2455

Website: www.kirinadvisors.com